Endpoints NewsOriginal article
Kyverna says long-term data bolster FDA submission for rare autoimmune CAR-T
NDA FilingPositive
AI Analysis
Summary
Kyverna Therapeutics reported positive one-year data for a rare autoimmune CAR-T therapy in stiff person syndrome patients, supporting an FDA submission for this condition affecting approximately 6,000 US patients.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
positive one-year results in stiff person syndrome patients
Importance:6/10
Sentiment:
0.70
rare diseaseautoimmuneCAR-Tstiff person syndromelong-term data
Read the original article
Published by Endpoints News on September 24, 2026 10:02 AM